Russell G Higbee from 9321 Buttonwood St, Orlando, FL 32825, age 73, Phone: 4073820392

Doctor Of Veterinary Medicine

Address:

2501 Discovery Dr SUITE 300, Orlando, FL 32826

License #:

6680 - Expired

Issued Date:

Dec 22, 1997

Renew Date:

Nov 1, 2010

Expiration Date:

Oct 31, 2012

Type:

Veterinarian

Qa/Qc/Glp/Rso/Bso - Sanofi Pasteur, Vaxdesign Campus

view source

Position:

Manager QA/QC/GLP/RSO/BSO at sanofi pasteur, VaxDesign Campus, Professor, Burnett School of Biomedical Sciences, College of Medicine at University of Central Florida

Location:

Orlando, Florida

Industry:

Biotechnology

Work:

sanofi pasteur, VaxDesign Campus since 2004
Manager QA/QC/GLP/RSO/BSO
University of Central Florida since 2004
Professor, Burnett School of Biomedical Sciences, College of Medicine

Russell Higbee

view source

Us Patents

Disease Model Incorporation Into An Artificial Immune System (Ais)
view source
US Patent:

7709256, May 4, 2010
Filed:

Jun 15, 2006
Appl. No.:

11/453003
Inventors:

William L. Warren - Orlando FL, US
Russell Higbee - Orlando FL, US
Eric Mishkin - Winter Springs FL, US
Heather Fahlenkamp - Broken Arrow OK, US
Michael Rivard - Natick MA, US
Assignee:

Vaxdesign Corp. - Orlando FL
International Classification:

C12N 5/06
US Classification:

435372, 435373
Abstract:

The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.

Disease Model Incorporation Into An Artificial Immune System (Ais)
view source
US Patent:

7771999, Aug 10, 2010
Filed:

Mar 12, 2008
Appl. No.:

12/047107
Inventors:

William L. Warren - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Russell G. Higbee - Orlando FL, US
Eric M. Mishkin - Winter Springs FL, US
Michael D. Rivard - Natick MA, US
Santosh Pawar - Orlando FL, US
Assignee:

VaxDesign Corp. - Orlando FL
International Classification:

C12N 5/06
US Classification:

435372, 435373
Abstract:

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Automatable Artificial Immune System (Ais)
view source
US Patent:

7785883, Aug 31, 2010
Filed:

Mar 15, 2006
Appl. No.:

11/375033
Inventors:

William L. Warren - Orlando FL, US
Robert Parkhill - Orlando FL, US
Michael N. Nguyen - Orlando FL, US
Heather Fahlenkamp - Broken Arrow OK, US
Russell Higbee - Orlando FL, US
Donald Drake, III - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
David Moe - Orlando FL, US
Assignee:

Vax Design Corp. - Orlando FL
International Classification:

C12N 5/08
US Classification:

435372, 435373
Abstract:

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.

Artificial Immune System: Methods For Making And Use
view source
US Patent:

7855074, Dec 21, 2010
Filed:

Apr 28, 2005
Appl. No.:

11/116234
Inventors:

William L. Warren - Orlando FL, US
Heather Fahlenkamp - Oviedo FL, US
Russell Higbee - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
Conan Li - Orlando FL, US
Mike Nguyen - Orlando FL, US
Robert Parkhill - Orlando FL, US
Darrell J. Irvine - Arlington MA, US
Gwendalyn J. Randolph - New York NY, US
Nir Hacohen - Brookline MA, US
Bruce Torbett - Encinitas CA, US
Assignee:

VaxDesign Corp. - Orlando FL
International Classification:

C12N 5/08
US Classification:

435372, 435373
Abstract:

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

In Vitro Germinal Centers
view source
US Patent:

8003385, Aug 23, 2011
Filed:

Feb 17, 2010
Appl. No.:

12/707563
Inventors:

Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Conan Li - Los Altos CA, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Eric Mishkin - Winter Springs FL, US
William L. Warren - Orlando FL, US
Assignee:

Sanofi Pasteur Vax Design Corp. - Orlando FL
International Classification:

C12N 5/06
C12N 5/02
US Classification:

435326, 435375, 435377
Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

In Vitro Germinal Centers
view source
US Patent:

8003387, Aug 23, 2011
Filed:

Dec 21, 2006
Appl. No.:

11/642938
Inventors:

Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Eric Mishkin - Winter Springs FL, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Conan Li - Los Altos CA, US
William L. Warren - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Assignee:

Sanofi Pasteur Vaxdesign Corp. - Orlando FL
International Classification:

C12N 5/08
C12N 5/00
C12N 5/02
US Classification:

435373, 435375, 435377
Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

Artificial Lymphoid Tissue Equivalent
view source
US Patent:

8030070, Oct 4, 2011
Filed:

Jun 21, 2006
Appl. No.:

11/471514
Inventors:

Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Broken Arrow OK, US
Darrell J. Irvine - Arlington MA, US
William L. Warren - Orlando FL, US
Donald Drake, III - Orlando FL, US
Assignee:

Sanofi Pasteur Vaxdesign Corp. - Orlando FL
International Classification:

C12N 5/0781
C12N 5/0783
C12N 5/0784
US Classification:

435347, 435373, 435395
Abstract:

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.

Disease Model Incorporation Into An Artificial Immune System (Ais)
view source
US Patent:

8119403, Feb 21, 2012
Filed:

Mar 5, 2010
Appl. No.:

12/718084
Inventors:

William L. Warren - Orlando FL, US
Russell Higbee - Orlando FL, US
Eric Mishkin - Winter Springs FL, US
Heather Fahlenkamp - Cleveland OK, US
Michael Rivard - Natick MA, US
Assignee:

Sanofi Pasteur Vaxdesign Corp. - Orlando FL
International Classification:

C12N 5/00
C12N 5/02
US Classification:

435375, 435382, 435404
Abstract:

The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.